

## Abbexa Licenses Novel Telomerase Reagents from Children's Medical Research Institute

Cambridge, UK and Sydney, Australia. 30<sup>th</sup> November, 2015

Abbexa Ltd and Children's Medical Research Institute (CMRI) are pleased to announce today that they have entered into an Exclusive License, Supply and Distribution Agreement for the following telomerase research reagents: primary antibody and antigenic peptide for telomerase immunoprecipitation and telomerase high-expressing cell pellets. These novel telomerase research products represent powerful and important tools for superior purification of telomerase and more effective and accurate telomerase studies. This agreement makes these research products available to the academic research community for non-commercial research purposes. The agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.

The portfolio of novel telomerase reagents was developed by leading telomere and telomerase research groups located at CMRI and led by Dr Scott Cohen, Associate Professor Tracy Bryan and Professor Roger Reddel. The reagents fill a currently unmet need for tools to purify telomerase, precisely quantify telomerase enzymatic activity and source high levels of telomerase protein.

Prof. Reddel from CMRI said *"These telomerase reagents are unprecedented as tools to produce and purify telomerase. Historically, this has been challenging and unreliable due to the very low expression of telomerase in cells and paucity of effective commercially available antibodies. These reagents will facilitate more effective and specific analysis of telomerase biology. We are delighted to make them available through Abbexa to the global scientific community."*

Sabrina Calabressi, Managing Director for Abbexa commented *"We are committed to providing high quality products to the scientific community to facilitate medical research and new discoveries. CMRI's optimised telomerase reagents will give researchers the ability to simply and accurately obtain large amounts of purified and active telomerase for their telomerase studies or drug development"*.

The telomerase reagents and cell pellets now available from Abbexa include:

**hTERT Antibody (abx120550, CMRI 276-294)**

CMRI 276-294 is a polyclonal anti-sheep hTERT antibody used to achieve high-level telomerase enrichment via a mild immunoprecipitation procedure. The antibody was initially generated by Dr Lorel Colgin against the peptide antigen corresponding to hTERT amino acids 276 to 294.

**hTERT Peptide (abx069990, Antigenic release peptide for CMRI 276-294)**

The antigenic release peptide complements immunoprecipitation of telomerase by facilitating the dissociation of the CMRI 276-294 antibody – telomerase enzyme complex under mild conditions, resulting in retention of telomerase activity.

**HEK-293T Telomerase Over-Expressing Cell Pellet (abx069991, Telomerase high-expressing cell pellets)**

Telomerase over-expressing HEK-293T cell pellets allow large scale manufacture and purification of active telomerase. Compared to other commercially available products, these cells have much higher levels of telomerase, good stability and batch-to-batch consistency with retained telomerase enzyme activity.

**hTERT Antibody and hTERT peptide are also sold together as a kit (abx098990).**

**The reagents have been published in a number of high-impact publications:**

- Tong et al., ATM and ATR Signaling Regulate the Recruitment of Human Telomerase to Telomeres. **Cell Reports**. (2015) doi: 10.1016/j.celrep.2015.10.041. [Epub ahead of print]
- Moye et al., Telomeric G-quadruplexes are a substrate and site of localization for human telomerase. **Nature Communications**. (2015) 6: 7643
- Tomlinson et al., Two-step mechanism involving active-site conformational changes regulates human telomerase DNA binding. **Biochemical Journal**. 2015 Jan; 465(2):347-57.
- Stern et al. Telomerase recruitment requires both TCAB1 and Cajal bodies independently. **Mol. Cell. Biol.**(2012) 32(13):2384.
- Jurczyk et al. Direct involvement of the TEN domain at the active site of human telomerase. **Nucleic Acids Research** (2011) Mar;39(5):1774-88.
- Cohen SB and Reddel RR. A sensitive direct human telomerase activity assay. **Nature Methods**. (2008) April; 4(5): 355-60.
- Cohen et al. Protein composition of catalytically active human telomerase from immortal cells. **Science**. (2007) March 30; 315(5820): 1850-3.



### **About Abbexa**

Abbexa Ltd. is a worldwide supplier and distributor of biological tools for the life science, pharmaceutical development and biotechnology sectors. Abbexa's product range includes primary and secondary antibodies, proteins, ELISA kits and enzymes as well as other kits and tools. Abbexa also offers a custom peptide and antibody production pipeline.

[www.abbexa.com](http://www.abbexa.com)



### **About Children's Medical Research Institute**

Established in 1958 by Sir Lorimer Dods, its goals are to advance and enhance paediatric health care for the benefit of the community. Today, CMRI is committed to excellence in biomedical science, engaging in fundamental research into the causes, prevention, early diagnosis, and relief or cure of disease in children. Many diseases that affect children, such as cancer and epilepsy, have the same origins in adults. [www.cmri.org.au](http://www.cmri.org.au)



### **About Bio-Link Australia**

Bio-Link Australia Pty. Ltd. is a life sciences commercialisation company which facilitates partnerships in the biopharma, diagnostics, medical devices and research reagents industries. Bio-Link has offices in Sydney and Melbourne, Australia, and clients including leading Australian and international medical research institutions, biotechnology and medical device companies.

[www.bio-link.com](http://www.bio-link.com)